SCHEMBL3759049

SCHEMBL3759049

O=C(O)CCc1ccc(Nc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 4/20 0.58
ITGAV P06756 4/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
CHRM1 P11229 1/20 0.57
DDX3X O00571 1/20 0.56
AKR1C3 P42330 1/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
MMP2 P08253 2/20 0.53
MMP13 P45452 2/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
ALDH1A1 P00352 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
GAA P10253 1/20 0.50
AURKA O14965 1/20 0.50
AURKB Q96GD4 1/20 0.50
PKM P14618 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058857 0.89 NPC1 (0.57) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL3771108 0.87 ALDH1A1 (0.61) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL19004803 0.86 NPC1 (0.55) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL26299109 0.86 MEN1 (0.69) MEN1KMT2ADDX3XAKR1C3NPC1
SCHEMBL8224952 0.85 NPC1 (0.54) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL22703572 0.85 NPC1 (0.54) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL8219447 0.81 MEN1 (0.58) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL13058943 0.81 MEN1 (0.58) ITGB3ITGAVMEN1KMT2ADDX3X
SCHEMBL3767781 0.80 AKR1C3 (0.73) MEN1KMT2ADDX3XAKR1C3NPC1
SCHEMBL239690 0.79 MEN1 (0.75) MEN1KMT2ADDX3XAKR1C3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486370-B2 Heterocyclic ligands for integrin imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-16 US disclosed
US-8486370-B2 Heterocyclic ligands for integrin imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-16 US disclosed
US-8486370-B2 Heterocyclic ligands for integrin imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-16 US disclosed
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-09 US disclosed
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-09 US disclosed
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-09 US disclosed
WO-2008031016-A2 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-13 WO disclosed
WO-2008031016-A2 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310455-A1 Heterocyclic Ligands for Integrin Imaging and Therapy ITGA1, ITGAL, ITGA4 ITGB3 9/4885ITGAV 5/4885MEN1 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.